{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(1)"],"submitter":["Anagnostou E"],"pubmed_abstract":["<h4>Unlabelled</h4><h4>Background</h4>There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.<h4>Methods</h4>This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of int"],"journal":["Molecular autism"],"pagination":["16"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3539865"],"repository":["biostudies-literature"],"pubmed_title":["Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial."],"pmcid":["PMC3539865"],"pubmed_authors":["Wang AT","Kushki A","Anagnostou E","Chaplin W","Pepa L","Hollander E","Tanel N","Wasserman S","Soorya L","Bartz J","Halpern D"],"additional_accession":[]},"is_claimable":false,"name":"Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.","description":"<h4>Unlabelled</h4><h4>Background</h4>There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.<h4>Methods</h4>This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of int","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Dec","modification":"2026-07-15T08:41:00.102Z","creation":"2026-07-02T03:11:50.628Z"},"accession":"S-EPMC3539865","cross_references":{"pubmed":["23216716"],"doi":["10.1186/2040-2392-3-16"]}}